Effective anticancer treatments have dramatically improved the outcome of patients with cancer, but cardiac toxicity reduces their clinical efficacy in a non-negligible percentage of patients. Sacubitril/valsartan is a new paradigm in the treatment of chronic heart failure, with a reduced ejection fraction due to the enhancement of natriuretic peptides' properties when coupled with a blocking effect on the angiotensin II type 1 (AT1) receptors. As with other clinical conditions of heart failure with potentially reversible declines in cardiac function, a wearable cardioverter defibrillator (WCD) is a valid tool for protection against sudden death until recovery occurs. We report a case series of four patients with chemotherapy-related acute cardiac failure with severely reduced cardiac function. They were successfully treated with sacubitril/valsartan while being protected from malignant arrhythmias using a wearable cardioverter defibrillator until the recovery of cardiac function. Sacubitril/valsartan was confirmed to be effective in anthracycline-related cardiac toxicity and the wearable cardioverter defibrillator should be considered as a support tool even in the oncology patient.
OnBehalf Stress Echo 2020 study group of the Italian Society of Cardiovascular Imaging Background B-lines (also known as comets) by lung ultrasound (LUS) are a marker of pulmonary congestion and interstitial pulmonary edema during stress echocardiography (SE). Aim To assess the prognostic value of B-lines during SE. Methods We prospectively performed transthoracic echocardiography (TTE) and LUS (4-site simplified scan) evaluation at rest and peak stress in 1437 patients (age 63 ± 11 years; 874 males, 61%) referred for exercise (n = 581), vasodilator (n = 819: dipyridamole, n= 809 and adenosine, n= 10) or dobutamine (n = 37) SE for known or suspected coronary artery disease or heart failure. B-lines were assessed by LUS with a 4-site simplified scan (total score from 0-1, dry lung, to 40, alveolar pulmonary edema). Follow-up (median 16 months) was completed in all. Results B-lines were 1.14 [0-35] at rest and increased during stress (2.10 [0-40], p<.001). At individual patient analysis, B-lines appeared de novo/increased (≥2 points) during stress in 306 (21.3%), remained absent or fixed in 1097 (76.3%) and decreased/disappeared in 34 (2.4%). At follow-up, there were 174 events: 17 deaths, 14 non-fatal myocardial infarctions, 51 hospital admissions for acute heart failures, and 92 late (> 3 months from SE) myocardial revascularizations. At multivariable analysis, stress-induced regional wall motion abnormalities (Hazard Ratio, HR, 2.842, 95% Confidence Intervals, CI: 2.016-4.005, p<.0.001) and B-lines change during stress (HR 1.471, 95% CI: 1.054-2.052, p=.022) were independent predictors. Kaplan-Meier curves showed progressively worsening event-free survival for 943 pts with absent (score 0-1), 333 with mild (2-5), 90 with moderate (6-10) and 71 with severe (>10) B-lines at peak stress: see figure. Conclusion B-lines by LUS are a useful adjunct to regional wall motion abnormalities for risk stratification during SE. The presence and number of B-lines during stress allow a titration of risk. The outcome is darker with more comets in the SE sky. Abstract P1403 Figure. Survival curves and peak stress B-lines
Background The vascular access represents a crucial phase in the management of complications related to the implantation of devices. After the use of the axillary vein, which allows the elimination of intrathoracic complications as well as the subclavian crush of the catheters, the ultrasound–guided approach could represent the next step for the reduction of vascular complications. Experience All implants performed (n = 86) by an independent operator who implemented ultrasound to minimize complications related to central access were reviewed. During the first phase, the ultrasound–guided approach involved the study of vascular accesses before the start of the implant. The assessment took place before the preparation of the sterile field, for the localization of the axillary approach and for the study of the anatomical variants. It was immediately followed by the use of skin marks. The use of markers made it possible to attempt surgical isolation of the cephalic vein as a first approach. In case of failure, or the need for multiple accesses, the transition to central access could be facilitated by the presence of skin markers. This approach have not significantly modified the probability of successful axillary vein puncture without the use of venography (75% vs 71%, p NS). In the last phase all implants were performed with ultrasound–guided puncture with sterile technique before skin incision (n = 26). The procedures involved dual chamber (61%), single chamber (19%), CRTD (11%), dual chamber ICD. Ultrasound showed all cases of hypoplastic cephalic vein (15%). In the first three months of implementation, the success rate was 71.4% with 1 self–healing case of apical pneumothorax. In the following months the success rate rapidly increased to 94.1% (p < 0.05) with no pneumo or hemothorax. The median time to effective puncture was 28 seconds (8–450sec) in the second phase. It was possible to isolate the cephalic vein in 40% of cases for two or three chamber implants. Conclusions The ultrasound study of the accesses performed before the incision allows to identify the anatomy and to define the course of the axillary vascular system and its relationships. When performed with a sterile approach, it allows direct ultrasound–guided puncture before the surgical incision, with a high success rate from the early stages of implementation.
Effective anticancer treatments have dramatically improved the outcome of cancer patients but cardiac toxicity reduces their clinical efficacy in a non–negligible percentage of patients. Sacubitril/valsartan is a new paradigm in the treatment of chronic heart failure with reduced ejection fraction due to the enhancement of natriuretic peptides’ properties when coupled with a blocking effect on the AT1 angiotensin receptors. As with other clinical conditions of heart failure with potentially reversible declines in cardiac function, the wearable cardioverter defibrillator is a valid tool for protection against sudden death until recovery occurs. We report a case series of four patients with chemotherapy–related acute cardiac failure with severely reduced cardiac function. They were successfully treated with sacubitril/valsartan while being protected from malignant arrhythmias by the use of a wearable cardioverter defibrillator until the recovery of cardiac function. Sacubitril/valsartan was confirmed to be effective in anthracycline–related cardiac toxicity and the wearable cardioverter defibrillator should be considered as a support tool even in the oncology patient.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.